ब्राज़ील - पुर्तगाली - CPVS (Compêndio de Produtos Veterinários)

kÖnig do brasil ltda - diazepam; hidantoÍna; - anestÉsicos, sedativos e similares

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

cosmed industria de cosmeticos e medicamentos s.a. - domperidona - antiemeticos e antinauseantes

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

cimed industria s.a - domperidona - antiemeticos e antinauseantes

यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - neoplasias prostáticas - terapia endócrina - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamida - neoplasias prostáticas - terapia endócrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplasias do peito - agentes antineoplásicos - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

sun farmacÊutica do brasil ltda - acetato de abiraterona - agentes antineoplÁsicos

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

dr. reddys farmacÊutica do brasil ltda - acetato de abiraterona - antineoplasico

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

sandoz do brasil indÚstria farmacÊutica ltda - acetato de abiraterona - outros antineoplasicos

ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

eurofarma laboratÓrios s.a. - estrogenos assocs a outros farmacos exclusive androgenos